A Phase II Study of Melflufen for Persistent or Recurrent Multiple Myeloma


Full Title

OP-106: A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination with Dexamethasone in Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Pomalidomide and/or anti-CD38 Monoclonal Antibody


In this study, researchers are assessing the safety and effectiveness of an investigational drug called melflufen for patients with multiple myeloma that has continued growing or came back despite prior treatment with pomalidomide and/or daratumumab. Melflufen may stop multiple myeloma growth by binding to and damaging the DNA in cancer cells. Once inside the cell, it is converted to melphalan, a drug already used to treat multiple myeloma. Doctors believe that giving melflufen may result in higher levels of melphalan inside the cancer cell than conventional melphalan treatment.

Patients will also receive dexamethasone, a steroid drug which is routinely used in multiple myeloma treatment. Melflufen is given intravenously (by vein), and dexamethasone is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have multiple myeloma that came back or continued to grow despite at least two regimens of previous treatment that included pomalidomide and/or daratumumab.
  • At least 3 weeks must pass between the completion of previous chemotherapy and entry into the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Hani Hassoun at 212-639-3228.